Literature DB >> 32272245

Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration.

Shria Kumar1, David C Metz2, David E Kaplan3, David S Goldberg4.   

Abstract

BACKGROUND & AIMS: Expert consensus mandates retesting for eradication of Helicobacter pylori infection after treatment, but it is not clear how many patients are actually retested. We evaluated factors associated with retesting for H pylori in a large, nationwide cohort.
METHODS: We performed a retrospective cohort study of patients with H pylori infection (detected by urea breath test, stool antigen, or pathology) who were prescribed an eradication regimen from January 1, 1994 through December 31, 2018 within the Veterans Health Administration (VHA). We collected data on demographic features, smoking history, socioeconomic status, facility poverty level and academic status, and provider specialties and professions. The primary outcome was retesting for eradication. Statistical analyses included mixed-effects logistic regression.
RESULTS: Of 27,185 patients prescribed an H pylori eradication regimen, 6486 patients (23.9%) were retested. Among 7623 patients for whom we could identify the provider who ordered the test, 2663 patients (34.9%) received the order from a gastroenterological provider. Female sex (odds ratio, 1.22; 95% CI, 1.08-1.38; P = .002) and history of smoking (odds ratio, 1.24; 95% CI, 1.15-1.33; P < .001) were patient factors associated with retesting. There was an interaction between method of initial diagnosis of H pylori infection and provider who ordered the initial test (P < .001). There was significant variation in rates of retesting among VHA facilities (P < .001).
CONCLUSIONS: In an analysis of data from a VHA cohort of patients with H pylori infection, we found low rates of retesting after eradication treatment. There is significant variation in rates of retesting among VHA facilities. H pylori testing is ordered by nongastroenterology specialists two-thirds of the time. Confirming eradication of H pylori is mandatory and widespread quality assurance protocols are needed.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic; Resistance; Response to Therapy; Risk Factor

Mesh:

Substances:

Year:  2020        PMID: 32272245      PMCID: PMC7541590          DOI: 10.1016/j.cgh.2020.03.059

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  42 in total

Review 1.  Helicobacter pylori Infection.

Authors:  Sheila E Crowe
Journal:  N Engl J Med       Date:  2019-03-21       Impact factor: 91.245

2.  Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among a Medicaid population.

Authors:  M Thamer; N F Ray; S C Henderson; C S Rinehart; C R Sherman; J H Ferguson
Journal:  Med Care       Date:  1998-05       Impact factor: 2.983

Review 3.  Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications.

Authors:  Monique M Gerrits; Arnoud H M van Vliet; Ernst J Kuipers; Johannes G Kusters
Journal:  Lancet Infect Dis       Date:  2006-11       Impact factor: 25.071

4.  How well is Helicobacter pylori treated in usual practice?

Authors:  Kumaresan Yogeswaran; Grant Chen; Lawrence Cohen; Mary Anne Cooper; Elaine Yong; Eugene Hsieh; Corwyn Rowsell; Fred Saibil; Jill Tinmouth
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

5.  Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding.

Authors:  Hyuk Yoon; Dong Ho Lee; Eun Sun Jang; Jaihwan Kim; Cheol Min Shin; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Sook-Hayng Jeong; Nayoung Kim
Journal:  World J Gastroenterol       Date:  2015-02-28       Impact factor: 5.742

6.  Quality of care for older patients with cancer in the Veterans Health Administration versus the private sector: a cohort study.

Authors:  Nancy L Keating; Mary Beth Landrum; Elizabeth B Lamont; Samuel R Bozeman; Steven H Krasnow; Lawrence N Shulman; Jennifer R Brown; Craig C Earle; William K Oh; Michael Rabin; Barbara J McNeil
Journal:  Ann Intern Med       Date:  2011-06-07       Impact factor: 25.391

7.  Seroprevalence of Helicobacter pylori Infection in a National Cohort of Veterans With Noncardia Gastric Adenocarcinoma.

Authors:  Shria Kumar; David C Metz; David E Kaplan; David S Goldberg
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-20       Impact factor: 11.382

8.  Is Helicobacter pylori being treated appropriately? A study of inpatients and outpatients in a tertiary care centre.

Authors:  Jose Nazareno; David K Driman; Paul Adams
Journal:  Can J Gastroenterol       Date:  2007-05       Impact factor: 3.522

9.  Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study.

Authors:  Shria Kumar; David C Metz; Susan Ellenberg; David E Kaplan; David S Goldberg
Journal:  Gastroenterology       Date:  2019-10-22       Impact factor: 22.682

Review 10.  Review article: the global emergence of Helicobacter pylori antibiotic resistance.

Authors:  I Thung; H Aramin; V Vavinskaya; S Gupta; J Y Park; S E Crowe; M A Valasek
Journal:  Aliment Pharmacol Ther       Date:  2015-12-23       Impact factor: 8.171

View more
  2 in total

1.  The Influence of Past Metronidazole Exposure on the Outcome of Helicobacter pylori Eradication.

Authors:  Younghee Choe; Joon Sung Kim; Hyun Ho Choi; Dae Bum Kim; Jae Myung Park; Jung Hwan Oh; Tae Ho Kim; Dae Young Cheung; Woo Chul Chung; Byung-Wook Kim; Sung Soo Kim
Journal:  Front Microbiol       Date:  2022-03-25       Impact factor: 5.640

Review 2.  Role of lipid rafts in persistent Helicobacter pylori infection: a narrative review.

Authors:  Renjie Liu; Yuzuo Chen; Lu Yang; Mingjiang Bie; Baoning Wang
Journal:  Ann Transl Med       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.